Welcome to our dedicated page for Trinity Biotech Plc SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Trinity Biotech plc (TRIB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 20-F annual reports and Form 6-K current reports. As a foreign private issuer listed on the Nasdaq Stock Market, Trinity Biotech uses these filings to furnish information on its human diagnostics and diabetes management business, financing arrangements and governance matters.
Form 6-K reports for TRIB frequently include press releases as exhibits, covering topics such as regulatory approvals for offshored and outsourced manufacturing of its TrinScreen HIV and Uni-Gold HIV rapid tests, expansion of its high-capacity HbA1c column system for the Premier Hb9210 analyzer, collaboration on epigenetic analysis for the EpiCapture prostate cancer test, and regulatory clearance for the PreClara Ratio preeclampsia testing service. Other 6-K filings reference amendments to credit agreements with Perceptive Credit Holdings entities, warrant issuances, and results of annual general meetings, including resolutions on auditor appointment and share capital authorities.
Users interested in Trinity Biotech’s capital structure and risk profile can review filings that discuss its term-loan facility, amendments and restatements of its credit agreement, and arrangements that allow potential conversion of portions of debt and certain obligations into equity. Filings also document interactions with Nasdaq regarding listing requirements, such as notices of non-compliance with minimum bid price and market value of publicly held shares thresholds, and subsequent confirmation that the company has regained compliance.
Stock Titan enhances access to these documents with tools that surface key elements of each filing, helping readers quickly identify material related to product approvals, financing terms, shareholder votes and other regulatory disclosures. This allows investors, analysts and other stakeholders to examine the official record of Trinity Biotech’s activities as reported to the U.S. Securities and Exchange Commission.
Trinity Biotech plc is updating its Form F-1 prospectus to cover the resale by selling shareholders of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. The ADSs trade on Nasdaq under the symbol TRIB and the last reported sale price on March 9, 2026 was $0.7010.
The supplement incorporates Form 6‑K materials filed March 10, 2026, including a press release describing technical breakthroughs for the company’s next‑generation CGM+ continuous glucose monitoring platform and a trading/business update that discloses a limited waiver and a covenant deferral under its Credit Agreement through July 1, 2026, and operational actions such as outsourcing Uni‑Gold™ HIV manufacturing.
Trinity Biotech plc is updating its Form F-1 prospectus to cover the resale by selling shareholders of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. The ADSs trade on Nasdaq under the symbol TRIB and the last reported sale price on March 9, 2026 was $0.7010.
The supplement incorporates Form 6‑K materials filed March 10, 2026, including a press release describing technical breakthroughs for the company’s next‑generation CGM+ continuous glucose monitoring platform and a trading/business update that discloses a limited waiver and a covenant deferral under its Credit Agreement through July 1, 2026, and operational actions such as outsourcing Uni‑Gold™ HIV manufacturing.
Trinity Biotech plc updates its prospectus to register for resale up to 705,659,320 Ordinary Shares, represented by up to 35,282,966 ADSs. The supplement incorporates Form 6-K reports filed March 10, 2026, describing technical breakthroughs for its next‑generation CGM+ continuous glucose monitoring platform and a trading and business update.
The company reports substantial multi‑day clinical-data improvements in glucose measurement accuracy (material reduction in MARD), anticipates initiating a pivotal clinical trial in 2026, and states the CGM+ design targets modularity, multimodal sensing, and AI-native analytics. Separately, Trinity obtained a limited waiver and a covenant deferral under its credit agreement through July 1, 2026.
Trinity Biotech plc updates its prospectus to register for resale up to 705,659,320 Ordinary Shares, represented by up to 35,282,966 ADSs. The supplement incorporates Form 6-K reports filed March 10, 2026, describing technical breakthroughs for its next‑generation CGM+ continuous glucose monitoring platform and a trading and business update.
The company reports substantial multi‑day clinical-data improvements in glucose measurement accuracy (material reduction in MARD), anticipates initiating a pivotal clinical trial in 2026, and states the CGM+ design targets modularity, multimodal sensing, and AI-native analytics. Separately, Trinity obtained a limited waiver and a covenant deferral under its credit agreement through July 1, 2026.
Trinity Biotech plc reports major technical progress on its next-generation, calibration‑free CGM+ continuous glucose monitoring platform, supported by more than 650 days of clinical testing data. The updated sensor and electronics architecture materially improved glucose measurement accuracy across multi‑day wear, indicating the system can meet modern CGM accuracy standards.
The company also developed a needle‑free insertion process and a modular device design aimed at lowering costs and improving sustainability versus current market‑leading CGMs. CGM+ uses multimodal sensing and AI‑native analytics to generate personalized metabolic health insights, and Trinity Biotech anticipates initiating a pivotal clinical trial in 2026, targeting regulatory submissions in key global markets afterward.
Trinity Biotech plc reports major technical progress on its next-generation, calibration‑free CGM+ continuous glucose monitoring platform, supported by more than 650 days of clinical testing data. The updated sensor and electronics architecture materially improved glucose measurement accuracy across multi‑day wear, indicating the system can meet modern CGM accuracy standards.
The company also developed a needle‑free insertion process and a modular device design aimed at lowering costs and improving sustainability versus current market‑leading CGMs. CGM+ uses multimodal sensing and AI‑native analytics to generate personalized metabolic health insights, and Trinity Biotech anticipates initiating a pivotal clinical trial in 2026, targeting regulatory submissions in key global markets afterward.
Trinity Biotech plc filed a Form 6-K sharing a trading and business update and disclosing amendments to its credit covenants. The company obtained a limited waiver of covenant 8.16 and a deferral of a scheduled change to covenant 8.15 under its Credit Agreement with Perceptive Credit Holdings III, both effective through July 1, 2026.
Operationally, Trinity Biotech is advancing a Comprehensive Transformation Plan aimed at improving long-term profitability. It received local regulatory approval in February 2026 to outsource and offshore production of its Uni-Gold HIV rapid test, enabling the final transition of manufacturing. Strong demand for Uni-Gold HIV and growing traction for TrinScreen are expected to increase the share of rapid HIV products in 2026 revenue, but order patterns and the outsourcing transition are anticipated to increase quarter‑on‑quarter revenue variability and shift some HIV revenue from Quarter 1 into Quarter 2 and from Quarter 2 into Quarter 3.
In diabetes care, the Premier Hb9210 HbA1c laboratory solution earned IFCC Gold Classification for 2026 and obtained multiple regulatory clearances for a next‑generation high‑capacity HbA1c column system. Trinity Biotech is intensifying commercial efforts in the United States, Brazil, and distributor markets, while also consolidating certain haemoglobin manufacturing processes at other group sites to expand capacity and reduce costs.
Trinity Biotech plc filed a Form 6-K sharing a trading and business update and disclosing amendments to its credit covenants. The company obtained a limited waiver of covenant 8.16 and a deferral of a scheduled change to covenant 8.15 under its Credit Agreement with Perceptive Credit Holdings III, both effective through July 1, 2026.
Operationally, Trinity Biotech is advancing a Comprehensive Transformation Plan aimed at improving long-term profitability. It received local regulatory approval in February 2026 to outsource and offshore production of its Uni-Gold HIV rapid test, enabling the final transition of manufacturing. Strong demand for Uni-Gold HIV and growing traction for TrinScreen are expected to increase the share of rapid HIV products in 2026 revenue, but order patterns and the outsourcing transition are anticipated to increase quarter‑on‑quarter revenue variability and shift some HIV revenue from Quarter 1 into Quarter 2 and from Quarter 2 into Quarter 3.
In diabetes care, the Premier Hb9210 HbA1c laboratory solution earned IFCC Gold Classification for 2026 and obtained multiple regulatory clearances for a next‑generation high‑capacity HbA1c column system. Trinity Biotech is intensifying commercial efforts in the United States, Brazil, and distributor markets, while also consolidating certain haemoglobin manufacturing processes at other group sites to expand capacity and reduce costs.
Trinity Biotech PLC Schedule 13G shows Novus Diagnostics Ltd. reports beneficial ownership of 1,119,988 American Depositary Shares, representing 5.99% of the ADS class based on 18,710,000 ADS outstanding as reported. The filing states Novus has sole voting and dispositive power for these 1,119,988 ADS.
Trinity Biotech plc entered a standby equity purchase agreement allowing up to $25,000,000 of ADS purchases and registers up to 35,282,966 ADSs (each ADS = 20 ordinary shares). The Company delivered 175,537 Commitment ADSs as a fee and paid a $35,000 structuring fee. Under the Purchase Agreement the per-ADS purchase price equals 0.97 times the lowest daily VWAP in a three-Trading-Day period or 0.95 times the VWAP in a one-Trading-Day period. The Investor is subject to a 4.99% beneficial ownership cap; separate Perceptive conversion instruments include a 9.9% cap. The prospectus registers resale by YA II PN, LTD., and Trinity will not receive proceeds from resales; proceeds to Trinity, if any, would result only from ADSs Trinity elects to sell to the Investor under the Purchase Agreement. Shares outstanding figures and other capitalization metrics are reported in the prospectus.
Trinity Biotech plc files a prospectus supplement registering for resale up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs, for sale by selling shareholders.
The supplement also furnishes Form 6-K disclosures: (1) a Nasdaq notice that the company does not meet the MVPHS $15,000,000 requirement and has until August 18, 2026 to regain compliance, and (2) a Standby Equity Purchase Agreement with YA II PN, Ltd. providing an up-to $25,000,000 financing commitment (term to February 24, 2029), an Aggregate Advance Share Cap of 35,107,429 ADSs, and a Commitment Fee of 175,537 ADSs.
Trinity Biotech plc registered for resale up to 35,282,966 ADSs (each ADS = 20 ordinary shares). The ADSs include 175,537 Commitment ADSs delivered as a structuring fee and up to 35,107,429 ADSs issuable under a Standby Equity Purchase Agreement providing for up to $25,000,000 of ADS purchases.
The Purchase Agreement dated February 24, 2026 allows the company, at its option, to sell ADSs to YA II PN, LTD. during a commitment period ending the earlier of February 24, 2029 or purchase of the commitment amount. Pricing is 0.97× VWAP for a three-Trading-Day period or 0.95× VWAP for a one-Trading-Day period. The prospectus states the Selling Securityholder will pay resale expenses and the company will not receive proceeds from resales; the company may receive gross proceeds up to $25 million only from ADSs it elects to sell to the Investor under the Purchase Agreement. Shares outstanding were reported as 374,406,640 ordinary shares as of February 22, 2026. The filing also discloses Nasdaq bid-price and market-value deficiency notices, with cure periods extending into August 2026.
Trinity Biotech plc has entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., giving the company the right, but not the obligation, to sell up to $25 million of American Depositary Shares (ADSs), each representing 20 class A ordinary shares.
ADSs sold under the agreement will be priced at 95% of the ADS volume‑weighted average price (VWAP) for a one‑day pricing period or 97% of the lowest VWAP over a three‑day period. The facility runs until the earlier of February 24, 2029 or when the full $25 million is purchased, is subject to an effective resale registration statement, and includes a 4.99% beneficial ownership cap for the investor. Trinity Biotech will pay a $35,000 structuring fee and a commitment fee satisfied by issuing 175,537 ADSs.
Trinity Biotech plc received a Nasdaq notice that it no longer meets the Nasdaq Global Select Market requirement that listed securities maintain a minimum market value of publicly held shares of $15,000,000 based on the last 30 consecutive business days.
The company’s ADSs remain listed and trading on the Nasdaq Global Select Market under the symbol TRIB, with no immediate effect from the notice. Trinity Biotech has 180 calendar days, until August 18, 2026, to regain compliance by having its market value of publicly held shares exceed $15,000,000 for at least 10 consecutive business days, or it may seek transfer to The Nasdaq Capital Market if it meets those listing standards.
If it fails to regain compliance or transfer by that date, Nasdaq may move to delist the ADSs, a decision the company could appeal to a hearings panel, though success is not assured.